| Literature DB >> 29734850 |
Yu Shi1, Weihong Yan1, Qiaoyan Lin1, Weimin Wang2.
Abstract
Objective We investigated the protective effect of icariin on myocardial infarction-induced cardiac remodeling. Methods A cardiac remodeling model was constructed by ligating rats' coronary artery. Different icariin and CD147 concentrations were administered in the model group, and echocardiography was used to detect systolic function, screening out ideal experimental concentrations. The ventricular systolic function, myocardial apoptosis rate, and expression of collagen type I (Col I), Col III, CD147, matrix metalloproteinase 9 (MMP-9), and tissue inhibitor of metalloproteinase 1 (TIMP-1) were detected by hematoxylin-eosin staining, TUNEL assay, and western blot. MMP-9 activity was evaluated by gelatin zymography. Results The expression of Col I, Col III, CD147, and MMP-9 was higher, the expression of TIMP-1 was lower, and the maximal rates of left ventricular pressure rise and fall (+dp/dtmax and -dp/dtmax, respectively) were lower in model than control rats. The expression of CD147, MMP-9, Col I, and Col III was lower, the expression of TIMP-1 was higher, and the +dp/dtmax and -dp/dtmax were higher in the icariin than model group. The apoptosis rate was lower in the icariin and icariin + CD147 groups than control group. Conclusion Icariin attenuated myocardial apoptosis following myocardial infarction by apoptosis rate reduction and CD147/MMP-9 pathway inhibition.Entities:
Keywords: CD147/MMP-9 pathway; Myocardial infarction; apoptosis; cardiac remodeling; collagen; icariin
Mesh:
Substances:
Year: 2018 PMID: 29734850 PMCID: PMC6023067 DOI: 10.1177/0300060518762060
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Sequences of PCR primers of detected genes
| Genes | Primer | Sequence (5′–3′) |
|---|---|---|
| Bax | Forward | AGACAGGGGCCTTTTTGCTAC |
| Reverse | AATTCGCCGGAGACACTCG | |
| Bcl-2 | Forward | GCTACCGTCGTGACTTCGC |
| Reverse | CCCCACCGAACTCAAAGAAGG | |
| Caspase-3 | Forward | CTCGCTCTGGTACGGATGTG |
| Reverse | TCCCATAAATGACCCCTTCATCA | |
| Col I | Forward | GCTCCTCTTAGGGGCCACT |
| Reverse | ATTGGGGACCCTTAGGCCAT | |
| Col III | Forward | CTGTAACATGGAAACTGGGGAAA |
| Reverse | CCATAGCTGAACTGAAAACCACC | |
| CD147 | Forward | GTGGCGTTGACATCGTTGG |
| Reverse | CTATGTACTTCGTATGCAGGTCG | |
| MMP-9 | Forward | GCAGAGGCATACTTGTACCG |
| Reverse | TGATGTTATGATGGTCCCACTTG | |
| TIMP-1 | Forward | CGAGACCACCTTATACCAGCG |
| Reverse | ATGACTGGGGTGTAGGCGTA | |
| GAPDH | Forward | AGGTCGGTGTGAACGGATTTG |
| Reverse | GGGGTCGTTGATGGCAACA |
PCR, polymerase chain reaction; Col I, collagen type I; Col III, collagen type III; MMP-9, matrix metalloproteinase 9; TIMP-1, tissue inhibitor of metalloproteinase 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Figure 1.(a) Electrocardiograms of rats in the sham and model groups. (b) Hematoxylin–eosin staining of the rats’ heart tissues in different groups. Scale bar = 100 µm.
Hemodynamic changes after treatment with various dosages of icariin
| LVDd (cm) | LVDs (cm) | LVAWd (cm) | LVEF (%) | |
|---|---|---|---|---|
| Group | ||||
| Control | 0.49 ± 0.04 | 0.25 ± 0.02 | 0.15 ± 0.03 | 79.12 ± 2.84 |
| Sham | 0.50 ± 0.05 | 0.24 ± 0.03 | 0.15 ± 0.02 | 78.86 ± 4.13 |
| Model (dosage of icariin; mg/kg per day) | ||||
| 0 | 0.68 ± 0.12* | 0.49 ± 0.11* | 0.09 ± 0.02* | 48.86 ± 3.79* |
| 3 | 0.62 ± 0.15* | 0.46 ± 0.05* | 0.11 ± 0.03* | 51.14 ± 4.42* |
| 6 | 0.57 ± 0.08*# | 0.37 ± 0.08*# | 0.12 ± 0.02*# | 62.81 ± 2.88*# |
| 12 | 0.53 ± 0.05*# | 0.30 ± 0.05*# | 0.14 ± 0.03# | 72.12 ± 4.12*# |
| 20 | 0.53 ± 0.06*# | 0.29 ± 0.06*# | 0.14 ± 0.11# | 74.01 ± 5.81*# |
Data are presented as mean ± standard deviation.
LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic diameter; LVAWd, end-diastolic left ventricular anterior wall thickness; LVEF, left ventricular ejection fraction.
*P < 0.05 compared with control group; #P < 0.05 compared with model group (0 mg/kg per day). n = 3.
Hemodynamic changes after treatment with various dosages of CD147
| Dosage of CD147 (mg/kg per day) | LVDd (cm) | LVDs (cm) | LVAWd (cm) | LVEF (%) |
|---|---|---|---|---|
| 5 | 0.61 ± 0.04 | 0.35 ± 0.04 | 0.12 ± 0.03 | 65.11 ± 4.17 |
| 10 | 0.67 ± 0.05Δ | 0.48 ± 0.05* | 0.09 ± 0.02* | 51.12 ± 3.14* |
| 15 | 0.68 ± 0.05Δ | 0.51 ± 0.06* | 0.09 ± 0.01* | 50.09 ± 2.88* |
Data are presented as mean ± standard deviation.
LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic diameter; LVAWd, end-diastolic left ventricular anterior wall thickness; LVEF, left ventricular ejection fraction.
*P < 0.05 compared with model rats treated with 5 mg/kg per day of CD147. n = 3.
Hemodynamic changes of rats among different groups
| Group | HR(beats per minute) | MAP(mmHg) | LVEDP(mmHg) | +dp/dtmax(mmHg/s) | −dp/dtmax(mmHg/s) |
|---|---|---|---|---|---|
| Control | 441.0 ± 35.5 | 115.2 ± 11.7 | 5.8 ± 1.2 | 4481.5 ± 279.4 | 167.9 ± 11.2 |
| Sham | 451.7 ± 51.4 | 117.5 ± 10.8 | 5.9 ± 1.4 | 4417.6 ± 208.5 | 165.4 ± 10.8 |
| Model | 520.9 ± 74.3* | 91.0 ± 7.2* | 25.1 ± 5.2* | 3519.5 ± 115.6* | 131.8 ± 7.5* |
| Icariin | 455.9 ± 34.8# | 106.9 ± 8.5# | 10.2 ± 3.1*# | 4275.8 ± 194.2# | 171.9 ± 12.5# |
| Icariin + CD147 | 511.2 ± 47.5*#Δ | 96.5 ± 7.4*#Δ | 17.5 ± 4.1*#Δ | 3961.8 ± 127.4*#Δ | 152.1 ± 11.0*#Δ |
Data are presented as mean ± standard deviation.
HR, heart rate; MAP, mean arterial pressure; LVEDP, left ventricular end-diastolic pressure; +dp/dtmax, maximal rate of left ventricular pressure rise; −dp/dtmax, maximal rate of left ventricular pressure fall.
*P < 0.05 compared with control group; #P < 0.05 compared with model group; ΔP < 0.05 compared with icariin group. n = 3.
HW/BW ratio and myocardial apoptosis rate changes among different groups
| Group | HW/BW ratio (mg/g) | Apoptosis rate (%) |
|---|---|---|
| Control | 6.17 ± 0.09 | 0.00 ± 0.00 |
| Sham | 6.20 ± 0.11 | 0.05 ± 0.03 |
| Model | 7.02 ± 0.14* | 17.81 ± 4.12* |
| Icariin | 6.37 ± 0.12*# | 4.75 ± 0.67*# |
| Icariin + CD147 | 6.89 ± 0.15*#Δ | 5.12 ± 0.54*#Δ |
Data are presented as mean ± standard deviation.
HW, heart weight; BW, body weight.
*P < 0.05 compared with control group; #P < 0.05 compared with model group; ΔP < 0.05 compared with icariin group. n = 3.
Figure 2.Apoptosis rate and expression levels of Bcl-2, Bax, and caspase-3 in rat hearts in different groups. (a) TUNEL staining of rats’ heart tissues in different groups; Scale bar = 200 µm. (b) mRNA expression levels. (c, d) Protein expression levels. *P < 0.05 compared with the control group; #P < 0.05 compared with the model group; ΔP < 0.05 compared with the icariin group. n = 3.
Figure 3.Expression levels of Col I and Col III of rat hearts in different groups. (a) mRNA expression levels. (b, c) Protein expression levels. *P < 0.05 compared with the control group; #P < 0.05 compared with the model group; ΔP < 0.05 compared with the icariin group. n = 3. Col I, collagen type I; Col III, collagen type III.
Figure 4.Expression levels of CD147, MMP-9, and TIMP-1 of rat hearts in different groups. (a) mRNA expression levels. (b) Protein expression levels. (d) Activity of MMP-9. *P < 0.05 compared with the control group; #P < 0.05 compared with the model group; ΔP < 0.05 compared with the icariin group. n = 3.